Keywords: biogen, idec, agrees, 200m, deal, ucb, oral

Biogen Idec agrees $200M deal for UCB's oral MS drug

Article | 09 October 2006

Print This

Belgium's UCB and US drugmaker Biogen Idec have entered a global collaboration to jointly develop and commercialize CDP323 for the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in